Radioactive 'Seeker' drug targets tough prostate cancer in new trial
NCT ID NCT07259213
Summary
This early-stage study is testing a new radioactive drug called 161Tb-RAD402 in men with advanced prostate cancer that has stopped responding to standard hormone-blocking treatments. The drug is designed to seek out and deliver radiation directly to prostate cancer cells. The main goals are to find a safe dose and see if the treatment shows early signs of slowing the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icon Cancer Centre Hollywood
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Conditions
Explore the condition pages connected to this study.